Variability and biases introduced through sample purification are commonly cited as the largest limiting factors in the progression of EV-based platforms into clinical diagnostics and therapeutics. Common nanoparticle characterization techniques, such as NTA and TRPS, are unable to discriminate EVs from particles that co-purify, and are subject to errors in data interpretation. These co-purified particles influence EV counts and limit the ability to link clinical observations to measured data. ExoView™ bypasses these challenges by measuring only specific EVs that exhibit target surface antigens without the need for purification. The platform works with as little as 35µL of sample and provides EV phenotype, size and count direct from biological fluids onto a functionalized array.
Key Feature include:
· Reduction in time, cost and biases associated with sample purification.
· A single sample workflow in which size, count and EV phenotype can be measured.
· Specific measurement of EVs and not containment lipoproteins.
· Small sample volume - just a few µls of sample required.
· Measurement of samples as close to biological source as possible - reducing the biases associated with sample preparation.
Common issues with purification